Morgan Stanley
IMUX icon

Morgan Stanley’s Immunic IMUX Stock Holding History

Morgan Stanley’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.65M Buy
328,854
+119,753
+57% +$1.07M ﹤0.01% 4356
2025
Q4 		$1.12M Sell
209,101
-101,211
-33% -$741K ﹤0.01% 5125
2025
Q3 		$2.74M Sell
310,312
-52,541
-14% -$463K ﹤0.01% 4589
2025
Q2 		$2.53M Buy
362,853
+306,092
+539% +$2.81M ﹤0.01% 4557
2025
Q1 		$619K Sell
56,761
-53,715
-49% -$580K ﹤0.01% 5237
2024
Q4 		$1.1M Buy
110,476
+71,405
+183% +$900K ﹤0.01% 5038
2024
Q3 		$645K Buy
39,071
+36,531
+1,438% +$520K ﹤0.01% 5280
2024
Q2 		$28.2K Sell
2,540
-491
-16% -$6.1K ﹤0.01% 6356
2024
Q1 		$40K Sell
3,031
-246
-8% -$3.2K ﹤0.01% 6300
2023
Q4 		$49.2K Buy
3,277
+68
+2% +$833 ﹤0.01% 6389
2023
Q3 		$47.2K Sell
3,209
-2,502
-44% -$48.1K ﹤0.01% 6191
2023
Q2 		$143K Sell
5,711
-46,737
-89% -$783K ﹤0.01% 5790
2023
Q1 		$781K Buy
52,448
+5,010
+11% +$93K ﹤0.01% 5006
2022
Q4 		$664K Buy
47,438
+45,649
+2,552% +$1.24M ﹤0.01% 5088
2022
Q3 		$56K Sell
1,789
-2,135
-54% -$89.4K ﹤0.01% 6358
2022
Q2 		$136K Buy
3,924
+1,543
+65% +$98.9K ﹤0.01% 6105
2022
Q1 		$269K Sell
2,381
-3,541
-60% -$410K ﹤0.01% 5754
2021
Q4 		$567K Buy
5,922
+4,843
+449% +$436K ﹤0.01% 5469
2021
Q3 		$95K Buy
1,079
+203
+23% +$20K ﹤0.01% 6408
2021
Q2 		$108K Buy
876
+870
+14,500% +$120K ﹤0.01% 6319
2021
Q1 		$1K Sell
6
-412
-99% -$69.9K ﹤0.01% 7350
2020
Q4 		$64K Buy
418
+349
+506% +$62.7K ﹤0.01% 6076
2020
Q3 		$13K Sell
69
-48
-41% -$7.86K ﹤0.01% 6188
2020
Q2 		$14K Buy
117
+102
+680% +$10.4K ﹤0.01% 6079
2020
Q1 		$1K Hold
15
– – ﹤0.01% 6463
2019
Q4 		$1K Hold
15
– – ﹤0.01% 6567
2019
Q3 		$1K Sell
15
-10
-40% -$1.34K ﹤0.01% 6548
2019
Q2 		$3K Sell
25
-21
-46% -$2.76K ﹤0.01% 6404
2019
Q1 		$4K Sell
46
-157
-77% -$13.8K ﹤0.01% 6357
2018
Q4 		$15K Sell
203
-204
-50% -$23.9K ﹤0.01% 6077
2018
Q3 		$45K Buy
407
+227
+126% +$593K ﹤0.01% 5903
2018
Q2 		$495K Buy
180
+73
+68% +$169K ﹤0.01% 5108
2018
Q1 		$291K Buy
107
+43
+67% +$98.7K ﹤0.01% 5300
2017
Q4 		$153K Buy
64
+61
+2,033% +$135K ﹤0.01% 5503
2017
Q3 		$6K Sell
3
-6
-67% -$7.83K ﹤0.01% 6257
2017
Q2 		$11K Sell
9
-72
-89% -$96.1K ﹤0.01% 6216
2017
Q1 		$129K Sell
81
-94
-54% -$172K ﹤0.01% 5505
2016
Q4 		$305K Buy
175
+159
+994% +$348K ﹤0.01% 5178
2016
Q3 		$39K Buy
16
+8
+100% +$19.7K ﹤0.01% 5686
2016
Q2 		$20K Sell
8
-16
-67% -$52.6K ﹤0.01% 5851
2016
Q1 		$88K Sell
24
-111
-82% -$386K ﹤0.01% 5373
2015
Q4 		$621K Buy
135
+123
+1,025% +$401K ﹤0.01% 4381
2015
Q3 		$19K Sell
12
-4
-25% -$20K ﹤0.01% 6063
2015
Q2 		$138K Sell
16
-14
-47% -$134K ﹤0.01% 5429
2015
Q1 		$295K Buy
30
+5
+20% +$46K ﹤0.01% 4989
2014
Q4 		$245K Buy
25
+24
+2,400% +$185K ﹤0.01% 5121
2014
Q3 		$6K Sell
1
-2
-67% -$18.9K ﹤0.01% 6297
2014
Q2 		$36K Buy
+3
New +$21.1K ﹤0.01% 5869

Other funds holding IMUX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
LCM
Laurion Capital Management New York $1.07B AUM 75.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $1.6B AUM 121.58% 1-Year Est. Return
6CM
683 Capital Management New York $1.08B AUM 85.52% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return